immunai

Silver Sponsor

Founded in December 2018, Immunai is on a mission to revolutionize drug discovery and development.

Central to our efforts is AMICA, a powerful data foundation strengthened through two key acquisitions: In March 2021, we acquired Dropprint Genomics, a Y-combinator-backed single-cell genomics software company that expanded our immune cell database. In July 2021, we acquired Nebion, a world leader in biocuration and data integration, whose expertly curated datasets have accelerated AMICA’s growth and broadened its application to inflammatory and oncological research.

With a global presence spanning New York City, Tel Aviv, Prague, and Zurich, our multidisciplinary team is dedicated to advancing innovation in drug discovery and development, bringing breakthrough therapies to patients worldwide.

website